Loading
JPXHealthcareBiotechnology
Latest quote
¥60.00
+¥2.00 · +3.45%
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Latest quote
¥60.00
+¥2.00 · +3.45%
Regular session · JST · Market data may be delayed.
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Day range
Current ¥60.00
52-week range
Current ¥60.00
Regular session · JST · Market data may be delayed.
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Day range
Current ¥60.00
52-week range
Current ¥60.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 84K JPY | 1.13M JPY | 72K JPY | 5.28M JPY | 15.41M JPY |
| Cost of goods sold | 29K JPY | 32K JPY | 413K JPY | 18.61M JPY | 38.44M JPY |
| Gross profit | 55K JPY | 1.1M JPY | −341K JPY | −13.33M JPY | −23.03M JPY |
| Research and development | — | 888.06M JPY | 775.56M JPY | 1.17B JPY | 1.14B JPY |
| Selling, general, and administrative | 1.3B JPY | 273.96M JPY | 379.18M JPY | 285.25M JPY | 317.15M JPY |
| Operating expenses | 1.3B JPY | 1.16B JPY | 1.15B JPY | 1.45B JPY | 1.45B JPY |
| Interest income | 16K JPY | 69K JPY | 12K JPY | 20K JPY | 27K JPY |
| Interest expense | — | — | — | 61K JPY | 362K JPY |
| Depreciation and amortization | — | — | 395K JPY | 16.72M JPY | 35.12M JPY |
| Operating income | −1.3B JPY | −1.16B JPY | −1.16B JPY | −1.47B JPY | −1.48B JPY |
| Net income | −1.3B JPY | −1.15B JPY | −1.17B JPY | −1.49B JPY | −1.48B JPY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
